Zymeworks Annual Revenue, Competitors, Number of Employees and Funding
Estimated Revenue & Financials
- Zymeworks's estimated annual revenue is currently $53M per year.
- Zymeworks received $110.6M in venture funding in June 2018.
- Zymeworks's estimated revenue per employee is $206,300
- Zymeworks's total funding is $181.7M.
- Zymeworks has 257 Employees.
- Zymeworks grew their employee count by 40% last year.
- Zymeworks currently has 23 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is Zymeworks?
Zymeworks Inc. (NYSE/TSX: ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC) and is expected to be the subject of an Investigational New Drug (IND) filing in 2018. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, and Janssen.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Johnny Kwan||Senior Manager||Email Available|
|Jacque Wilk||Director||Email Available|
|Mark Hollywood||Svp, Technical & Mfg Operations||Email Available|
|Hollings Renton||Member Board Of Directors|
|Susan Parker||Principal SAS Programmer||Email Available|
|Nels Royer||Associate Director, Clinical Program Management||Email Available|
|Rose Lai||Senior Medical Director||Email Available|
|Patrick Kaminker||Associate Director of Oncology||Email Available|
|Allison Fortenberry||Clinical Trials Manager||Email Available|
|Rupert Davies||Director, Pharmacokinetics||Email Available|
SAN FRANCISCO, Sept. 10, 2019 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") announced today that it has entered into a license agreement with ...
Advisor Group Inc. lifted its holdings in shares of Zymeworks Inc (NYSE:ZYME) by 42.7% during the second quarter, according to its most recent ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--. Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company ...
|2018-06-12||$110.6M||Undisclosed||Citigroup Global Markets Canada Inc||Article|
Zymeworks Executive Hires
|2018-09-20||Anthony Polverino||EVP Early Development/Chief Scientific Officer||Article|